NASDAQ:GDRX - GoodRx Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $16.37
  • Forecasted Upside: 122.40 %
  • Number of Analysts: 19
  • Breakdown:
  • 1 Sell Ratings
  • 12 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.24 (-3.16%)

This chart shows the closing price for GDRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New GoodRx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GDRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GDRX

Analyst Price Target is $16.37
▲ +122.40% Upside Potential
This price target is based on 19 analysts offering 12 month price targets for GoodRx in the last 3 months. The average price target is $16.37, with a high forecast of $47.00 and a low forecast of $6.00. The average price target represents a 122.40% upside from the last price of $7.36.

This chart shows the closing price for GDRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 19 contributing investment analysts is to hold stock in GoodRx.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 8 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 8 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 9 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 9 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 10 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 11 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 11 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 12 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/12/2022DA DavidsonInitiated CoverageNeutral$8.00Low
8/10/2022Morgan StanleyLower Price TargetEqual Weight$10.50 ➝ $10.00Low
8/9/2022SVB LeerinkBoost Price TargetMarket Perform$8.00 ➝ $11.00Low
8/9/2022Credit Suisse GroupBoost Price TargetNeutral$10.00 ➝ $11.00Low
8/9/2022The Goldman Sachs GroupBoost Price TargetNeutral$9.00 ➝ $10.00Low
8/9/2022Royal Bank of CanadaBoost Price TargetSector Perform$6.50 ➝ $11.00Low
8/9/2022BarclaysBoost Price TargetOverweight$12.00 ➝ $13.00Low
7/20/2022BarclaysLower Price TargetOverweight$15.00 ➝ $12.00Low
7/18/2022GuggenheimLower Price TargetBuy$17.00 ➝ $13.00Low
6/23/2022Royal Bank of CanadaReiterated RatingSector Perform$8.00 ➝ $6.50Low
6/22/2022Robert W. BairdLower Price TargetNeutral$7.00 ➝ $6.00Low
6/13/2022CowenLower Price TargetMarket Perform$22.00 ➝ $9.00Low
6/13/2022CowenLower Price Target$22.00 ➝ $9.00High
6/9/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$12.00 ➝ $9.00High
6/6/2022Bank of AmericaInitiated CoverageBuy ➝ Buy$11.00Medium
6/1/2022Robert W. BairdDowngradeOutperform ➝ Neutral$10.00 ➝ $7.00Medium
5/20/2022Morgan StanleyLower Price TargetEqual Weight$19.00 ➝ $10.50Low
5/12/2022Wells Fargo & CompanyLower Price Target$20.00 ➝ $9.00High
5/11/2022Deutsche Bank AktiengesellschaftLower Price Target$20.00 ➝ $10.00High
5/11/2022Credit Suisse GroupLower Price Target$22.00 ➝ $10.00High
5/10/2022BarclaysLower Price Target$28.00 ➝ $15.00High
5/10/2022SVB LeerinkDowngradeOutperform ➝ Market Perform$33.00 ➝ $10.00High
5/10/2022Raymond JamesDowngradeOutperform ➝ Market PerformHigh
5/10/2022Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$35.00 ➝ $8.00High
4/11/2022Wells Fargo & CompanyInitiated CoverageEqual Weight$20.00Low
4/6/2022GuggenheimInitiated CoverageBuy$24.00Low
4/5/2022Robert W. BairdBoost Price Target$17.00 ➝ $23.00N/A
3/17/2022Credit Suisse GroupLower Price TargetNeutral$27.00 ➝ $22.00High
3/15/2022Robert W. BairdUpgradeNeutral ➝ Outperform$17.00High
3/8/2022BarclaysLower Price TargetOverweight$35.00 ➝ $28.00Medium
3/2/2022Morgan StanleyLower Price TargetEqual Weight$41.00 ➝ $19.00High
3/2/2022Raymond JamesLower Price TargetOutperform$45.00 ➝ $30.00High
3/2/2022Deutsche Bank AktiengesellschaftLower Price TargetHold$25.00 ➝ $20.00High
3/1/2022JPMorgan Chase & Co.Lower Price TargetUnderweight$33.00 ➝ $20.00High
3/1/2022Evercore ISILower Price TargetOutperform$47.00 ➝ $28.00High
3/1/2022Bank of AmericaLower Price TargetNeutral$42.00 ➝ $28.00High
3/1/2022The Goldman Sachs GroupLower Price TargetBuy$43.00 ➝ $30.00High
3/1/2022SVB LeerinkLower Price TargetOutperform$49.00 ➝ $33.00High
3/1/2022Royal Bank of CanadaLower Price TargetOutperform$50.00 ➝ $35.00High
3/1/2022BarclaysLower Price TargetOverweight$43.00 ➝ $35.00High
3/1/2022Credit Suisse GroupDowngradeOutperform ➝ Neutral$41.00 ➝ $27.00High
3/1/2022CowenDowngradeOutperform ➝ Market Perform$49.00 ➝ $22.00High
1/25/2022Deutsche Bank AktiengesellschaftLower Price Target$44.00 ➝ $25.00Medium
1/7/2022The Goldman Sachs GroupInitiated CoverageBuy$43.00High
1/5/2022Robert W. BairdLower Price Target$40.00 ➝ $34.00High
12/21/2021StephensInitiated CoverageOverweight$45.00High
12/17/2021Morgan StanleyBoost Price TargetEqual Weight$38.00 ➝ $41.00Low
12/1/2021Jefferies Financial GroupInitiated CoverageBuy$47.00High
11/15/2021Deutsche Bank AktiengesellschaftLower Price TargetHold$47.00 ➝ $44.00Medium
11/11/2021BarclaysBoost Price TargetOverweight$45.00 ➝ $47.00Medium
11/11/2021SVB LeerinkLower Price TargetOutperform ➝ Outperform$56.00 ➝ $49.00Medium
10/1/2021Deutsche Bank AktiengesellschaftBoost Price TargetHold$37.00 ➝ $47.00High
9/14/2021Credit Suisse GroupBoost Price TargetOutperform$45.00 ➝ $52.00Low
8/31/2021BarclaysUpgradeEqual Weight ➝ Overweight$45.00Medium
8/24/2021CowenLower Price TargetOutperform$44.00 ➝ $42.00High
8/15/2021SVB LeerinkInitiated CoverageBuy$56.00High
8/13/2021Raymond JamesUpgradeMarket Perform ➝ Outperform$45.00Medium
7/2/2021Morgan StanleyBoost Price TargetEqual Weight$36.00 ➝ $38.00Low
5/27/2021Robert W. BairdInitiated CoverageNeutral$37.00Low
5/18/2021Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$50.00 ➝ $45.00Low
5/14/2021SVB LeerinkLower Price TargetOutperform$61.00 ➝ $56.00High
5/14/2021Royal Bank of CanadaLower Price TargetOutperform$56.00 ➝ $50.00High
5/14/2021BarclaysLower Price TargetEqual Weight$43.00 ➝ $33.00High
5/14/2021CitigroupBoost Price TargetBuy$53.00 ➝ $70.00High
5/10/2021CowenLower Price TargetOutperform$70.00 ➝ $58.00High
3/15/2021Credit Suisse GroupBoost Price TargetOutperform$49.00 ➝ $50.00Low
3/12/2021BarclaysBoost Price Target$35.00 ➝ $45.00Low
3/12/2021Deutsche Bank AktiengesellschaftBoost Price TargetHold$31.00 ➝ $37.00High
3/4/2021SVB LeerinkReiterated RatingBuy$61.00Medium
2/12/2021CowenBoost Price TargetOutperform$50.00 ➝ $70.00Low
1/25/2021GuggenheimInitiated CoverageBuy$52.00High
11/23/2020The Goldman Sachs GroupLower Price TargetNeutral$49.00 ➝ $44.00Low
11/20/2020Credit Suisse GroupLower Price TargetOutperform$60.00 ➝ $49.00Low
11/19/2020BarclaysLower Price TargetEqual Weight$55.00 ➝ $35.00High
11/19/2020Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$56.00High
11/18/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$36.00Low
11/18/2020JPMorgan Chase & Co.Reiterated RatingNeutral ➝ Underweight$29.00Low
11/18/2020Deutsche Bank AktiengesellschaftLower Price TargetHold$50.00 ➝ $31.00High
11/17/2020JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$29.00High
10/19/2020The Goldman Sachs GroupInitiated CoverageNeutral$48.00High
10/19/2020CowenInitiated CoverageOutperform$63.00High
10/19/2020Morgan StanleyInitiated CoverageOverweight$57.00High
10/19/2020JPMorgan Chase & Co.Initiated CoverageNeutral$59.00High
10/19/2020Raymond JamesInitiated CoverageEqual Weight ➝ Market Perform$57.00 ➝ $61.00High
10/19/2020Credit Suisse GroupInitiated CoverageOutperform$60.00High
10/19/2020Deutsche Bank AktiengesellschaftInitiated CoverageHold$50.00High
10/19/2020Royal Bank of CanadaInitiated CoverageSector Perform$55.00High
10/19/2020Bank of AmericaInitiated CoverageNeutral$58.00High
10/19/2020UBS GroupInitiated CoverageBuy$64.00High
10/19/2020BarclaysInitiated CoverageEqual Weight$53.00High
10/19/2020SVB LeerinkInitiated CoverageOutperform$61.00High
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
  • 7 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
  • 2 very positive mentions
  • 23 positive mentions
  • 13 negative mentions
  • 3 very negative mentions
  • 4 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
  • 3 very positive mentions
  • 29 positive mentions
  • 8 negative mentions
  • 3 very negative mentions
  • 2 very positive mentions
  • 16 positive mentions
  • 7 negative mentions
  • 2 very negative mentions
  • 5 very positive mentions
  • 10 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
  • 10 very positive mentions
  • 47 positive mentions
  • 2 negative mentions
  • 2 very negative mentions

Current Sentiment

  • 10 very positive mentions
  • 47 positive mentions
  • 2 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

GoodRx logo
GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was incorporated in 2015 and is headquartered in Santa Monica, California.
Read More

Today's Range

Now: $7.36
Low: $7.11
High: $7.88

50 Day Range

MA: $6.59
Low: $5.84
High: $7.81

52 Week Range

Now: $7.36
Low: $5.61
High: $48.05


6,653,394 shs

Average Volume

2,746,321 shs

Market Capitalization

$2.92 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of GoodRx?

The following Wall Street research analysts have issued reports on GoodRx in the last year: Bank of America Co., Barclays PLC, Cowen Inc, Cowen Inc., Credit Suisse Group AG, DA Davidson, Deutsche Bank Aktiengesellschaft, Evercore ISI, Guggenheim, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Raymond James, Robert W. Baird, Royal Bank of Canada, Stephens, SVB Leerink LLC, The Goldman Sachs Group, Inc., and Wells Fargo & Company.
View the latest analyst ratings for GDRX.

What is the current price target for GoodRx?

19 Wall Street analysts have set twelve-month price targets for GoodRx in the last year. Their average twelve-month price target is $16.37, suggesting a possible upside of 122.4%. Jefferies Financial Group Inc. has the highest price target set, predicting GDRX will reach $47.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $6.00 for GoodRx in the next year.
View the latest price targets for GDRX.

What is the current consensus analyst rating for GoodRx?

GoodRx currently has 1 sell rating, 12 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GDRX, but not buy more shares or sell existing shares.
View the latest ratings for GDRX.

What other companies compete with GoodRx?

How do I contact GoodRx's investor relations team?

GoodRx's physical mailing address is 233 WILSHIRE BLVD. SUITE 990, SANTA MONICA CA, 90401. The company's listed phone number is 855-268-2822 and its investor relations email address is [email protected] The official website for GoodRx is Learn More about contacing GoodRx investor relations.